LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Search

Glaukos Corp

Suletud

SektorTervishoid

102.88 -2.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

101.44

Max

103.19

Põhinäitajad

By Trading Economics

Sissetulek

114M

-20M

Müük

7.5M

151M

Aktsiakasum

-0.18

Kasumimarginaal

-13.139

Töötajad

1,094

EBITDA

123M

-7M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+46.65% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-301M

6.8B

Eelmine avamishind

105.61

Eelmine sulgemishind

102.88

Uudiste sentiment

By Acuity

60%

40%

281 / 344 Pingereas Healthcare

Glaukos Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 18:25 UTC

Suurimad hinnamuutused turgudel

Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

Võrdlus sarnastega

Hinnamuutus

Glaukos Corp Prognoos

Hinnasiht

By TipRanks

46.65% tõus

12 kuu keskmine prognoos

Keskmine 151.56 USD  46.65%

Kõrge 170 USD

Madal 136 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Glaukos Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

11

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

281 / 344 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat